Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 251 to 260 of 864 total matches.

Finasteride for Prevention of Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008  (Issue 1289)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to take finasteride (Proscar, and others) to prevent prostate cancer.
Med Lett Drugs Ther. 2008 Jun 30;50(1289):49-50 |  Show IntroductionHide Introduction

Advertisements for TNF Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Nov 17, 2008  (Issue 1299)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis (www.yahoo.com).
Med Lett Drugs Ther. 2008 Nov 17;50(1299):89 |  Show IntroductionHide Introduction

Low-Voltage Electronic Diagnostic Devices

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
Health care professionals may be asked about lowvoltage electronic devices now being used to diagnose and/or treat a number of health problems. Most are galvanometers that measure skin resistance to an electric current. The FDA classifies "devices that use resistance measurements to diagnose and treat various diseases" as Class III devices that require FDA approval prior to marketing. None of the devices reviewed here has such approval.
Med Lett Drugs Ther. 2008 Dec 1;50(1300):95-6 |  Show IntroductionHide Introduction

Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024  (Issue 1701)
1. F Tacke et al. An integrated view of anti-inflammatory and antifibrotic targets ...
Resmetirom (Rezdiffra – Madrigal), a thyroid hormone receptor-beta agonist, has received accelerated approval from the FDA for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis in adults. NASH has recently been renamed metabolic dysfunction-associated steatohepatitis (MASH). Resmetirom is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):65-6   doi:10.58347/tml.2024.1701a |  Show IntroductionHide Introduction

Safety of Canadian Drugs

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 2003  (Issue 1171)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
Questions have been raised in the US press recently about the safety of Canadian drugs. The process of drug approval in Canada is similar to that in the US (D Paul, Int J Med Marketing 2001; 1:224). More than 90% of drugs available in Canada have also been approved by the FDA. Most of these drugs come from the same manufacturers as drugs in the US. Health Canada takes longer on average to release drugs than the FDA does; more than half the drugs discontinued for safety reasons by the FDA between 1992 and 2001 had not been approved for use in Canada (NS Rawson and KI Kaitin, Ann Pharmacother...
Med Lett Drugs Ther. 2003 Dec 8;45(1171):100 |  Show IntroductionHide Introduction

Bivalirudin (Angiomax) For Angioplasty

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001  (Issue 1103)
or revascularization (3.2% vs 9.1%) than those receiving heparin (JA Bittl and F Feit, Am J Cardiol 1998; 82:43P ...
Bivalirudin is being promoted as an intravenous (IV) anticoagulant that can be used instead of heparin in patients with unstable angina undergoing coronary angioplasty.
Med Lett Drugs Ther. 2001 Apr 30;43(1103):37-8 |  Show IntroductionHide Introduction

Echinacea for Prevention and Treatment of Upper Respiratory Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002  (Issue 1127)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS ...
Echinacea, a plant also called purple coneflower, is widely used as a dietary supplement for prevention and treatment of colds.
Med Lett Drugs Ther. 2002 Apr 1;44(1127):29-30 |  Show IntroductionHide Introduction

Fondaparinux (Arixtra), A New Anticoagulant

   
The Medical Letter on Drugs and Therapeutics • May 13, 2002  (Issue 1130)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip replacement.
Med Lett Drugs Ther. 2002 May 13;44(1130):43-4 |  Show IntroductionHide Introduction

Fulvestrant (Faslodex) for Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2002  (Issue 1135)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
Fulvestrant (Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast cancer in postmenopausal women with disease progession on tamoxifen (Nolvadex, and others) or another antiestrogen.
Med Lett Drugs Ther. 2002 Jul 22;44(1135):65-6 |  Show IntroductionHide Introduction

Alefacept (Amevive) For Treatment of Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2003  (Issue 1154)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Med Lett Drugs Ther. 2003 Apr 14;45(1154):31-2 |  Show IntroductionHide Introduction